2023-11-13 13:00:00
THE ESSENTIAL
Allergists are developing a toothpaste specially formulated to deliver allergenic peanut proteins to areas of the oral cavity. This product, tested during a 48-week trial, was tolerated by 100% of participants who received the highest dose. No moderate or severe systemic reactions were observed in volunteers.
For several years, allergists have used oral immunotherapy, which involves introducing small amounts of an allergen over a period of time, to desensitize people with peanut allergies. Recently, doctors revealed that they are developing a toothpaste to combat peanut allergy. This last one is “specially formulated to deliver allergenic peanut proteins to immunologically active areas of the oral cavity.” According to experts, it has advantages over other approaches to allergy immunotherapy due to its targeted delivery and simplified administration, which promotes the goal of better compliance.
Peanut allergies: 32 people used the special toothpaste or a placebo
To test the effectiveness of this product, health professionals carried out a study, the results of which were presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, California. For the purposes of their work, the team recruited 32 adults, aged 18 to 55, suffering from a peanut allergy. Participants received either an increasing dose of toothpaste containing traces of peanuts or a placebo. During this 48-week trial, treatment safety was monitored during the dosing and maintenance phases. Blood tests, which show whether a person’s immune system responds to treatment with an allergen, were performed and oral food tests were also conducted.
100% of adults treated with peanut toothpaste tolerated the highest dose
According to the results, 100% of the volunteers who benefited from the toothpaste tolerated the highest dose of the “pre-specified protocol”. According to allergist William Berger, lead author of the research, no moderate or severe systemic reactions were observed in the participants. Non-systemic adverse reactions were mainly local (mouth itching), mild and transient. The treatment adherence rate was 97% and no dropouts were noted due to taking study drugs. “Oral mucosal immunotherapy appears to be a safe and practical option for adults with food allergies. The results support the continued development of this toothpaste in the pediatric population”concluded the practitioner in a press release.
Further long-term work is planned to evaluate continued use of toothpaste to provide long-term protection against accidental peanut ingestion.
1699881535
#toothpaste #reduce #risk #reactions